APO-QUINAPRIL/HCTZ TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE); HYDROCHLOROTHIAZIDE

متاح من:

APOTEX INC

ATC رمز:

C09BA06

INN (الاسم الدولي):

QUINAPRIL AND DIURETICS

جرعة:

20MG; 25MG

الشكل الصيدلاني:

TABLET

تركيب:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20MG; HYDROCHLOROTHIAZIDE 25MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

30/100

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0231789003; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2021-06-08

خصائص المنتج

_ _
_ _
_APO-QUINAPRIL/HCTZ (Quinapril and Hydrochlorothiazide Tablets)
PRODUCT MONOGRAPH_
_Page 1 of 61_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-QUINAPRIL/HCTZ
Quinapril and Hydrochlorothiazide Tablets
Tablets, 10 mg /12.5 mg, 20 mg /12.5 mg and 20 mg /25 mg Quinapril (as
Quinapril
Hydrochloride) / Hydrochlorothiazide, Oral
House Standard
Angiotensin Converting Enzyme Inhibitor/Diuretic
Apotex. Inc.
150 Signet Drive
Toronto Ontario
M9L 1T9
Submission Control Number: 283798
Date of Initial Authorization:
JUN
28,
2013
Date of Revision:
MAR 05, 2024
_ _
_ _
_APO-QUINAPRIL/HCTZ (Quinapril and Hydrochlorothiazide Tablets)
PRODUCT MONOGRAPH_
_Page 2 of 61_
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...................................................................................................
2
TABLE OF CONTENTS
......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................
4
1
INDICATIONS
.........................................................................................................................
4
1.1
Pediatrics (<18 years of age)
........................................................................................
4
1.2
Geriatrics (> 65 years of age)
.......................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................... 5
4
DOSAGE AND ADMINISTRATION
...................................................................................
5
4.1
Dosing Considerations
...............................................................................